{"id":44803,"date":"2025-10-28T13:50:28","date_gmt":"2025-10-28T05:50:28","guid":{"rendered":"https:\/\/flcube.com\/?p=44803"},"modified":"2025-10-28T13:50:29","modified_gmt":"2025-10-28T05:50:29","slug":"polymed-biopharmaceuticals-completes-pre%e2%80%91a-funding-round-led-by-caleb-capital-fuels-protac%e2%80%91focused-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44803","title":{"rendered":"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">PolyMed Biopharmaceuticals Co., Ltd., a Chinese\u2011based, internationally\u2011oriented biopharma innovator, announced the successful closure of its <strong>Pre\u2011A++ financing round<\/strong>. The deal was <strong>led by Caleb Capital<\/strong> and raised an undisclosed yet substantial amount of capital earmarked for accelerating the clinical development of its advanced drug pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile\"><strong>Company Profile<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Headquarters &amp; Global Presence<\/strong> \u2013 Based in Hangzhou with satellite offices in Shanghai and Boston.<\/li>\n\n\n\n<li><strong>Therapeutic Focus<\/strong> \u2013 Cancer, autoimmune disorders, and inflammation\u2011related diseases.<\/li>\n\n\n\n<li><strong>Technology Edge<\/strong> \u2013 Combines Artificial Intelligence, structural biology, and proteomics to tackle \u201cdifficult\u2011to\u2011drug\u201d targets through bifunctional molecules such as <strong>PROTACs<\/strong> and Antibody\u2011Drug Degraders.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-highlights\"><strong>Pipeline Highlights<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hpb-143-irak4-targeting-protac\"><strong>HPB\u2011143 \u2013 IRAK4\u2011Targeting PROTAC<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Induces selective degradation of IRAK4, a key driver of inflammation and oncogenesis.<\/li>\n\n\n\n<li><strong>Clinical\u2011Stage Advantages<\/strong> \u2013 Superior degradation potency, high oral bioavailability, and robust efficacy in pre\u2011clinical models.<\/li>\n\n\n\n<li><strong>Licensing &amp; Revenue Potential<\/strong> \u2013 Rights outside Greater China &amp; Southeast Asia were licensed to Photys Therapeutics (Boston) in February\u202f2025, yielding an upfront payment, share equity, and up to <strong>USD\u202f300\u202fmillion<\/strong> in milestone payments plus sales royalties.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hpb-092-flt3-irak4-dual-target-inhibitor\"><strong>HPB\u2011092 \u2013 FLT3\/IRAK4 Dual\u2011Target Inhibitor<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Profile<\/strong> \u2013 Simultaneous inhibition of FLT3 (common AML driver) and IRAK4.<\/li>\n\n\n\n<li><strong>Safety &amp; Efficacy<\/strong> \u2013 Designed for a broader AML patient population with a superior safety margin compared to existing FLT3 inhibitors.<\/li>\n\n\n\n<li><strong>Clinical Outlook<\/strong> \u2013 Expected to deliver more durable responses in acute myeloid leukemia (AML) patients.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact-of-the-funding\"><strong>Strategic Impact of the Funding<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Clinical Development<\/strong> \u2013 Capital will support GMP manufacturing, IND filings, and pivotal Phase\u202fI\/II trials for both HPB\u2011143 and HPB\u2011092.<\/li>\n\n\n\n<li><strong>Technology Scale\u2011Up<\/strong> \u2013 Enables expansion of AI\u2011driven lead\u2011optimization pipelines and proteomic screening platforms.<\/li>\n\n\n\n<li><strong>Market Positioning<\/strong> \u2013 Strengthens PolyMed\u2019s standing as a leader in PROTAC\u2011based therapeutics and positions the company for future licensing or partnership opportunities.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PolyMed Biopharmaceuticals Co., Ltd., a Chinese\u2011based, internationally\u2011oriented biopharma innovator, announced the successful closure of its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44808,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[20,3402,70],"class_list":["post-44803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-polymed-biopharmaceuticals","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"PolyMed Biopharmaceuticals Co., Ltd., a Chinese\u2011based, internationally\u2011oriented biopharma innovator, announced the successful closure of its Pre\u2011A++ financing round. The deal was led by Caleb Capital and raised an undisclosed yet substantial amount of capital earmarked for accelerating the clinical development of its advanced drug pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44803\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline\" \/>\n<meta property=\"og:description\" content=\"PolyMed Biopharmaceuticals Co., Ltd., a Chinese\u2011based, internationally\u2011oriented biopharma innovator, announced the successful closure of its Pre\u2011A++ financing round. The deal was led by Caleb Capital and raised an undisclosed yet substantial amount of capital earmarked for accelerating the clinical development of its advanced drug pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44803\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-28T05:50:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-28T05:50:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline\",\"datePublished\":\"2025-10-28T05:50:28+00:00\",\"dateModified\":\"2025-10-28T05:50:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2805.webp\",\"keywords\":[\"Finance\",\"Polymed Biopharmaceuticals\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44803#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44803\",\"name\":\"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2805.webp\",\"datePublished\":\"2025-10-28T05:50:28+00:00\",\"dateModified\":\"2025-10-28T05:50:29+00:00\",\"description\":\"PolyMed Biopharmaceuticals Co., Ltd., a Chinese\u2011based, internationally\u2011oriented biopharma innovator, announced the successful closure of its Pre\u2011A++ financing round. The deal was led by Caleb Capital and raised an undisclosed yet substantial amount of capital earmarked for accelerating the clinical development of its advanced drug pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44803\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2805.webp\",\"width\":1080,\"height\":608,\"caption\":\"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44803#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"PolyMed Biopharmaceuticals Co., Ltd., a Chinese\u2011based, internationally\u2011oriented biopharma innovator, announced the successful closure of its Pre\u2011A++ financing round. The deal was led by Caleb Capital and raised an undisclosed yet substantial amount of capital earmarked for accelerating the clinical development of its advanced drug pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44803","og_locale":"en_US","og_type":"article","og_title":"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline","og_description":"PolyMed Biopharmaceuticals Co., Ltd., a Chinese\u2011based, internationally\u2011oriented biopharma innovator, announced the successful closure of its Pre\u2011A++ financing round. The deal was led by Caleb Capital and raised an undisclosed yet substantial amount of capital earmarked for accelerating the clinical development of its advanced drug pipeline.","og_url":"https:\/\/flcube.com\/?p=44803","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-28T05:50:28+00:00","article_modified_time":"2025-10-28T05:50:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44803#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44803"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline","datePublished":"2025-10-28T05:50:28+00:00","dateModified":"2025-10-28T05:50:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44803"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44803#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2805.webp","keywords":["Finance","Polymed Biopharmaceuticals","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44803#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44803","url":"https:\/\/flcube.com\/?p=44803","name":"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44803#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44803#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2805.webp","datePublished":"2025-10-28T05:50:28+00:00","dateModified":"2025-10-28T05:50:29+00:00","description":"PolyMed Biopharmaceuticals Co., Ltd., a Chinese\u2011based, internationally\u2011oriented biopharma innovator, announced the successful closure of its Pre\u2011A++ financing round. The deal was led by Caleb Capital and raised an undisclosed yet substantial amount of capital earmarked for accelerating the clinical development of its advanced drug pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44803#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44803"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44803#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2805.webp","width":1080,"height":608,"caption":"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44803#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"PolyMed Biopharmaceuticals Completes Pre\u2011A++ Funding Round Led by Caleb Capital, Fuels PROTAC\u2011Focused Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2805.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44803"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44803\/revisions"}],"predecessor-version":[{"id":44809,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44803\/revisions\/44809"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44808"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}